Identification of Patients with Non-D, Non-C Irritable Bowel Syndrome and Treatment with Renzapride: An Exploratory, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- 10 May 2008
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 53 (12) , 3191-3200
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2006
- Functional Bowel DisordersGastroenterology, 2006
- A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipationGut, 2005
- The placebo effect in irritable bowel syndrome trials: a meta‐analysis1Neurogastroenterology & Motility, 2005
- The effects of the 5‐HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndromeNeurogastroenterology & Motility, 2005
- The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjectsAlimentary Pharmacology & Therapeutics, 2003
- Irritable bowel syndrome subtypes according to bowel habitEuropean Journal of Gastroenterology & Hepatology, 2003
- The 5-HT 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised ratGut, 2000
- Effect of alosetron on responses to colonic distension in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1998
- Reduction of rectal sensitivity and post‐prandial motility by granisetron, a 5 HT3‐receptor antagonist, in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1993